Akebia Therapeutics (AKBA) Tops Q4 EPS by 14c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.52), $0.14 better than the analyst estimate of ($0.66).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Bernstein sees downside risk to Apple's December quarter results
• Bernstein SocGen's Thoughts on McDonald's (MCD) Following Investor Day
• HSBC shuffles oil stocks ratings, upgrades BP and TotalEnergies to Buy